Patents by Inventor Andrew Faller

Andrew Faller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-dihydrofuro[2,3-b]pyridine compounds
    Patent number: 11214576
    Abstract: The present invention provides a compound of Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Andrew Faller
  • 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS
    Publication number: 20210070766
    Abstract: The present invention provides a compound of Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: June 14, 2019
    Publication date: March 11, 2021
    Inventors: Nicolas Jacques Francois DREYFUS, Andrew FALLER
  • Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
    Patent number: 7253198
    Abstract: The present invention relates to novel hydroxyethylamine compounds having Asp2 (?-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: August 7, 2007
    Assignee: Glaxo Group Limited
    Inventors: Emmanuel H Demont, Andrew Faller, David Timothy MacPherson, Peter Henry Milner, Alan Naylor, Sally Redshaw, Steven James Stanway, David R Vesey, Daryl S Walter
  • Hydroxyethylene compounds with Asp2 inhibitory activity
    Patent number: 7160905
    Abstract: The present invention relates to novel hydroxyethylene compounds having Asp2 (?-secretase. BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: January 9, 2007
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Andrew Faller, Peter Henry Milner, John Gerard Ward
  • Hydroxyethylamine derivatives for the treatment of alzheimer's disease
    Publication number: 20060025459
    Abstract: The present invention relates to novel hydroxyethylamine compounds having Asp2 (?-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Application
    Filed: December 3, 2003
    Publication date: February 2, 2006
    Inventors: Emmanuel Demont, Andrew Faller, David Macpherson, Peter Milner, Alan Naylor, Sally Redshaw, Steven Stanway, David Vesey, Daryl Walter
  • Benzamide derivatives, processes for their preparation, and their pharmaceutical use
    Patent number: 6992103
    Abstract: The present invention relates to novel hydroxyethylene compounds having Asp2 (?-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: January 31, 2006
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Andrew Faller, David Timothy MacPherson, Peter Henry Milner, Steven James Stanway, Leontine Saskia Trouw
  • Benzamide derivatives, processes for their preparation, and their pharmaceutical use
    Publication number: 20050085520
    Abstract: The present invention relates to novel hydroxyethylene compounds having Asp2 (?-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Application
    Filed: November 29, 2002
    Publication date: April 21, 2005
    Inventors: Andrew Faller, David Macpherson, Peter Milner, Steven Stanway, Leontine Trouw
  • Hydroxyethylene compounds with asp2 inhibitory activity
    Publication number: 20050038028
    Abstract: The present invention relates to hydroxyethylene compounds of formula (I), in which Ra represents a group of formula (a) or (b) where R1 represents —SO2R5, W1 represents CO or SO2, and the other variables are as defined in the claims, having Asp2 (?-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, compositions containing them, and their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Application
    Filed: November 29, 2002
    Publication date: February 17, 2005
    Inventors: Andrew Faller, Peter Milner, John Ward
  • (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates
    Publication number: 20040225006
    Abstract: Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.
    Type: Application
    Filed: May 14, 2004
    Publication date: November 11, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Gordon Bruton, Andrew Faller, Barry Sidney Orlek, Kishore Kalidas Rana, Graham Walker
  • Novel compounds
    Publication number: 20040209822
    Abstract: Compounds of the formula (I): 1
    Type: Application
    Filed: May 13, 2004
    Publication date: October 21, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Andrew Faller, Anne-Geraldine Rousseau, David Timothy MacPherson, Peter Henry Milner
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Publication number: 20040077727
    Abstract: A compound of formula (I) wherein: R is isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 22, 2004
    Applicant: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Patent number: 6673965
    Abstract: A compound of formula (I) wherein: R isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: January 6, 2004
    Assignee: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • 2,'3-Amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
    Publication number: 20030207923
    Abstract: Compounds of formula (I): wherein X1 is alkyl, sulphonyl or carboxy: X2 is hydrogen or alkyl; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated by s-CD23.
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Inventors: Andrew Faller, Anne-Geraldine Rousseau, David Timothy Macpherson, Peter Henry Milner
  • (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
    Publication number: 20030199571
    Abstract: Compounds of formula (I) wherein R is hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.
    Type: Application
    Filed: March 24, 2003
    Publication date: October 23, 2003
    Inventors: Gordon Bruton, Andrew Faller, Barry Sidney Orlek, Kishore Kalidas Rana, Graham Walker
  • Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
    Patent number: 6458779
    Abstract: Compounds of Formula (1) wherein: R is methyl substituted by one to three groups from alkyl, aryl, alkenyl, and alkynyl; n is ) or 1; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated y s-CD23.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: October 1, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Andrew Faller, David Timothy MacPherson, Peter Henry Milner, Jayshree Mistry, John Gerald Ward
  • Compounds
    Patent number: 6242467
    Abstract: Compounds of formula (I) wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R1 is aryl or heteroaryl, are useful in the treatment and prophylaxis of conditions mediated by CD23 or TNF.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: June 5, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Andrew Faller
  • Inhibitors of the production of S-CD23 and the secretion of TNF
    Patent number: 6235753
    Abstract: Inhibitors of the Production of s-CD23 and the secretion of TNF are provided.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: May 22, 2001
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Stuart Bailey, Andrew Faller, David Glynn Smith, Derek Richard Buckle